Skip to content

Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors

Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors: A Six-Week Randomized, Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01328665
Enrollment
44
Registered
2011-04-05
Start date
2011-04-30
Completion date
2012-06-30
Last updated
2013-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Disorder

Brief summary

This project evaluates the effectiveness of an intervention sought to reduce the physical effects of stress related to those issues that individuals cannot successfully communicate with anyone about. To do this, the investigators will be implementing a writing intervention over the course of the 6-week study. The investigators will be asking all participants to complete questionnaires over the course of the study period. The investigators are also asking participants to provide a small blood sample (from a fingerstick procedure) at two times during the study as well as saliva samples during that same time. The primary research question asks if this intervention procedure is effective. The investigators are evaluating total cholesterol, high sensitivity c-reactive protein, and cortisol.

Interventions

OTHERExpressive Writing

Writing intervention for cognitive appraisal of stressor.

Sponsors

Santa Clara University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 110 pounds in weight * Ability to fast for 8 hours prior to laboratory visit * Staff member at Santa Clara University * Certain level of inclusionary pretest stress measure

Exclusion criteria

* Hepatitis * Endocrine Disease * Kidney or Liver Disease * Cancer (in any form) * Cushing's disorder * Rheumatological disorders * Respiratory Disorders * Diabetes * High blood pressure * Low blood pressure * Heart or cardiovascular problems * Chemotherapy * Current use of alpha or beta blockers, steroids, or hormone replacements * Pregnant and/or breastfeeding mothers

Design outcomes

Primary

MeasureTime frameDescription
Change in Lipids from baselineWeek 1 and Week 6Lipid panel includes total cholesterol, High-density lipoproteins, low-density lipoprotein, and triglycerides.
Change in high-sensitivity c-Reactive Protein from baselineWeek 1 and Week 6
Change in Cortisol Awakening Response from BaselineWeek 1 and Week 6Measurement of Salivary Cortisol (hydrocortisone, compound-F) as a maximum difference between awakening and 30 minutes after awakening.

Secondary

MeasureTime frameDescription
Change in Perceived Global Stress over timeWeek 1, Week 3, Week 6Psychological measure of stress
Change in Organizational Stress over timeWeek 1, Week 3, Week 6Psychological measure of stress as a function of organizational involvement.
Change in Perception of Communication Restriction of Stressor over timeWeek 1, Week 3, Week 6Restrictedness of a communicative stressor

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026